Table 2 Multivariate analysis of rs6573816 on glioma progression in the different groups of male patients
From: Identification of a RAD51B enhancer variant for susceptibility and progression to glioma
Subgroup | Genotype | Median PFS (95%CI, months) | HRa (95% CI) | P |
|---|---|---|---|---|
All | GG | 30 (19–48) | 1.00 (reference) | |
GC | 12 (7–59) | 1.74 (0.90–3.34) | 0.097 | |
CC | 5 (NC) | 4.80 (0.61–37.50) | 0.135 | |
GC + CC | 11 (7–59) | 1.83 (0.97–3.45) | 0.061 | |
High grade glioma | GG | 14 (11–19) | 1.00 (reference) | |
GC | 11 (4–17) | 2.15 (1.05–4.40) | 0.036 | |
CC | 5 (NC) | 8.04 (0.96–67.13) | 0.054 | |
GC + CC | 10 (4–12) | 2.28 (1.14–4.57) | 0.020 | |
Underwent radiotherapy | GG | 29 (19–48) | 1.00 (reference) | |
GC | 11 (6–59) | 1.48 (0.68–3.21) | 0.318 | |
CC | 5 (NC) | 8.76 (1.01–76.11) | 0.049 | |
GC + CC | 11 (5–59) | 1.63 (0.78–3.43) | 0.200 |